Cargando…

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK

Nonalcoholic steatohepatitis (NASH) is recognized by hepatic lipid accumulation, inflammation, and fibrosis. No studies have evaluated the prolonged‐release pirfenidone (PR‐PFD) properties on NASH features. The aim of this study is to evaluate how PR‐PFD performs on metabolic functions, and provide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandoval‐Rodriguez, Ana, Monroy‐Ramirez, Hugo Christian, Meza‐Rios, Alejandra, Garcia‐Bañuelos, Jesus, Vera‐Cruz, Jose, Gutiérrez‐Cuevas, Jorge, Silva‐Gomez, Jorge, Staels, Bart, Dominguez‐Rosales, Jose, Galicia‐Moreno, Marina, Vazquez‐Del Mercado, Monica, Navarro‐Partida, Jose, Santos‐Garcia, Arturo, Armendariz‐Borunda, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049672/ https://www.ncbi.nlm.nih.gov/pubmed/32140659 http://dx.doi.org/10.1002/hep4.1474

Ejemplares similares

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
por: Escutia-Gutiérrez, Rebeca, et al.
Publicado: (2021)

The multifaceted role of pirfenidone and its novel targets
por: Macías-Barragán, José, et al.
Publicado: (2010)

Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio
por: Silva-Gomez, Jorge Antonio, et al.
Publicado: (2021)

Pirfenidone Accelerates Wound Healing in Chronic Diabetic Foot Ulcers: A Randomized, Double-Blind Controlled Trial
por: Gasca-Lozano, Luz E., et al.
Publicado: (2017)

PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases
por: Monroy-Ramirez, Hugo Christian, et al.
Publicado: (2021)

Oxidative and Fibrinolytic Mechanisms: Two Important Processes to Consider in Platelet Storage
por: Garcia-Bañuelos, Jesus Javier, et al.
Publicado: (2023)

Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice
por: Diaz-Palomera, Carlos Daniel, et al.
Publicado: (2022)

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2021)

Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current Knowledge
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2021)

Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice
por: Martinez-Alvarado, Yocasta, et al.
Publicado: (2023)

The Role of NRF2 in Obesity-Associated Cardiovascular Risk Factors
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2022)

Therapies Based on Nanoparticles for Eye Drug Delivery
por: Meza-Rios, Alejandra, et al.
Publicado: (2020)

A Fbxo48 inhibitor prevents pAMPKα degradation and ameliorates insulin resistance
por: Liu, Yuan, et al.
Publicado: (2021)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis
por: Picher-Martel, Vincent, et al.
Publicado: (2023)

Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2022)

Exploring the Role and Mechanism of pAMPKα-Mediated Dysregulation of Brf1 and RNA Pol III Genes
por: Wu, Teng, et al.
Publicado: (2021)

LKB1 suppression promotes cardiomyocyte regeneration via LKB1-AMPK-YAP axis
por: Qu, Shuang, et al.
Publicado: (2022)

Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial
por: Chávez-Iñiguez, Jonathan S., et al.
Publicado: (2021)

AMPK potentiation by LKB1 isoforms
por: Thibert, Chantal, et al.
Publicado: (2015)

Correction: Human adipose derived stem cells regress fibrosis in a chronic renal fibrotic model induced by adenine
por: Rivera-Valdés, Juan José, et al.
Publicado: (2018)

Human adipose derived stem cells regress fibrosis in a chronic renal fibrotic model induced by adenine
por: Rivera-Valdés, Juan José, et al.
Publicado: (2017)

Diabetes Impairs the Vascular Recruitment of Normal Stem Cells by Oxidant Damage, Reversed by Increases in pAMPK, Heme Oxygenase-1, and Adiponectin
por: Sambuceti, Gianmario, et al.
Publicado: (2009)

Novel Triamcinolone Acetonide-Loaded Liposomes Topical Formulation for the Treatment of Cystoid Macular Edema After Cataract Surgery: A Pilot Study
por: Gonzalez-De la Rosa, Alejandro, et al.
Publicado: (2019)

Simultaneous Administration of ADSCs-Based Therapy and Gene Therapy Using Ad-huPA Reduces Experimental Liver Fibrosis
por: Meza-Ríos, Alejandra, et al.
Publicado: (2016)

Prognostic Implication of pAMPK Immunohistochemical Staining by Subcellular Location and Its Association with SMAD Protein Expression in Clear Cell Renal Cell Carcinoma
por: Jung, Minsun, et al.
Publicado: (2019)

Roles of Nrf2 in Liver Diseases: Molecular, Pharmacological, and Epigenetic Aspects
por: Galicia-Moreno, Marina, et al.
Publicado: (2020)

Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models
por: Galicia-Moreno, Marina, et al.
Publicado: (2021)

The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice
por: Peterson, Stephen J., et al.
Publicado: (2009)

Connecting LKB1 and AMPK links metabolism with cancer
por: Moore, Pete
Publicado: (2003)

MLK3 Phophorylates AMPK Independently of LKB1
por: Luo, Lingyu, et al.
Publicado: (2015)

LKB1 and AMPK differentially regulate pancreatic β-cell identity
por: Kone, Marina, et al.
Publicado: (2014)

Fibrosis regression is induced by AdhMMP8 in a murine model of chronic kidney injury
por: Contreras-Salinas, Homero, et al.
Publicado: (2020)

Review article: vascular effects of PPARs in the context of NASH
por: Guixé‐Muntet, Sergi, et al.
Publicado: (2022)

LKB1 and AMPK and the cancer-metabolism link - ten years after
por: Hardie, D Grahame, et al.
Publicado: (2013)

LKB1 Regulates Lipid Oxidation During Exercise Independently of AMPK
por: Jeppesen, Jacob, et al.
Publicado: (2013)

Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study
por: Poo, Jorge Luis, et al.
Publicado: (2020)

Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C
por: Flores-Contreras, Lucia, et al.
Publicado: (2014)

The Natural Chemotherapeutic Capsaicin Activates AMPK through LKB1 Kinase and TRPV1 Receptors in Prostate Cancer Cells
por: Sánchez, Belén G., et al.
Publicado: (2022)

Delphinidin Ameliorates Hepatic Triglyceride Accumulation in Human HepG2 Cells, but Not in Diet-Induced Obese Mice
por: Parra-Vargas, Marcela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7sdd3kaghql93cfvmqeb6sl66h